Focus: Chugai Pharma is a 5,000+ employee Japanese pharmaceutical company focused on small-molecule drug development across oncology, immunology, nephrology, rare diseases, and gastroenterology. The company operates as part of the Roche group with significant R&D investment and recent capex expansion.
Profile data last refreshed 25m ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Chugai Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Chugai Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Chugai Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Chugai plans KRW 3 billion South Korea subsidiary: stock after-hours at EUR 34.56, plus 0.88 percent - AD HOC NEWS
Chugai plans KRW 3 billion South Korea subsidiary: stock after-hours at EUR 34.56, plus 0.88 percent AD HOC NEWS
Analysts cut fair value for Chugai Pharmaceutical stock to JPY 8,870 - AD HOC NEWS
Analysts cut fair value for Chugai Pharmaceutical stock to JPY 8,870 AD HOC NEWS
Roche culls myostatin candidate from obesity pipeline - pharmaphorum
Roche culls myostatin candidate from obesity pipeline pharmaphorum
Roche-owned Chugai Pharma to ramp up in-house output with 50% capex boost - Nikkei Asia
Roche-owned Chugai Pharma to ramp up in-house output with 50% capex boost Nikkei Asia
Japanese researchers win prestigious Lasker Award for medicine - Nikkei Asia
Japanese researchers win prestigious Lasker Award for medicine Nikkei Asia
Japan's Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351 - BioSpectrum Asia
Japan's Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351 BioSpectrum Asia
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo